Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

September’s top stories: Takeda gets EU approval for type 2 diabetes therapies

Takeda has received marketing authorisation from the European Commission for its three new type 2 diabetes therapies - Vipidia, Vipdomet and Incresync - while Dendreon has received European approval to market its prostate cancer therapy Provenge. Drugdevelopment-technology.com wraps up the key headlines from September 2013.

Go Top